{'fraction_non_alphanumeric': 0.032407407407407406, 'fraction_numerical': 0.024691358024691357, 'mean_word_length': 5.180952380952381, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors

Radioiodine therapy (RIT) is an accepted treatment for hyperthyroidism and a 555‐MBq (15‐mCi) dose is frequently used. We aimed to assess treatment outcome with this dose, and to identify predictors of successful treatment. An analysis of 478 treated patients demonstrated an overall four‐month cure rate of 79.5%; success rate was higher in patients with toxic multinodular goitre, solitary toxic adenoma, a smaller thyroid or less severe disease. This information may be of further assistance if variation in the dose of RIT is considered.